Sartorius Stedim Biotech Improves Core EBITDA Margin in 2025
Sartorius Stedim Biotech has released preliminary adjusted net profit figures for 2025, showing a 26.7% increase to €428 million (MEUR), along with a 17.3% rise in adjusted EBITDA to €914 million, representing a 2.8-point improvement in margin to 30.8%.
At €2.97 billion, the pharmaceutical industry supplier's revenue grew by 6.7% overall and by 9.6% at constant exchange rates, with all regions contributing to this increase.
"2025 was a very successful year for Sartorius Stedim Biotech. We are continuing on a growth trajectory with strong profitability," commented René Fáber, the company's Chief Executive Officer.
He highlighted the "excellent performance" of the high-margin recurring business in consumables for biopharmaceutical production, which accounts for the vast majority of revenue.
"As expected, equipment-related business remained weak, but showed encouraging signs of stabilization over the year. That's why we look to 2026 with optimism and confidence," he added.
For 2026, Sartorius Stedim Biotech expects its revenue to increase by approximately 6 to 10% at constant exchange rates. Its adjusted EBITDA margin is projected to rise to just over 31%, driven by volume and scale effects.
René Fáber is Chief Executive Officer & Director at Sartorius Stedim Biotech SA since 2023. Holds the position of Chairman at Sartorius Stédim FMT SAS. Serves as Vice Chairman at Sartorius Stedim Biotech (Beijing) Co., Ltd. Holds Director roles at Sartorius Stedim Japan KK, Sartorius Korea Biotech Co., Ltd., Sartorius Stedim (Shanghai) Trading Co., Ltd., Sartorius Albumedix Ltd., Sartorius Korea Operations LLC, and Sartorius Stedim BioOutsource Ltd. Member-Executive Board at Sartorius AG since 2002. Former Chairman-Supervisory Board at Sartorius Xell GmbH. Former Co-Managing Director & Member-Supervisory Board at Sartorius Stedim Biotech GmbH. Former Co-Managing Director at Sartorius Stedim North America Holding GmbH. Account Manager at Genentech, Inc. from 2016 to 2018. Vice President-Marketing & Product Management at Filtration Technology Corp. from 2014 to 2017. Education includes a doctorate from Technische Universität München and a graduate degree from Slovak University of Technology.
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key production sites are located in Germany, France and Puerto Rico.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
